Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome

Bone Marrow Transplantation
E JuvonenT Ruutu

Abstract

A male patient with hypereosinophilic syndrome (HES) underwent an allogeneic blood stem cell transplantation from a female donor following non-myeloablative conditioning consisting of a 2 Gy dose of TBI and fludarabine 30 mg/m(2) intravenously on three days. Before transplantation 100% of the mitotic bone marrow cells of the patient showed a clonal karyotype abnormality. Three months after the transplantation eosinophilia had resolved and a chromosome analysis revealed normal female karyotype. The present study shows that stem cell transplantation after non-myeloablative conditioning may have curative potential for HES.

References

May 1, 1995·British Journal of Haematology·T FukushimaM Tomonaga
Feb 16, 2000·Bone Marrow Transplantation·L VazquezJ F San Miguel

❮ Previous
Next ❯

Citations

Mar 29, 2006·Indian Journal of Pediatrics·C VenkateshB R Nammalwar
Oct 3, 2002·British Journal of Haematology·Naoto T UenoAndrey Y Zaritskey
Feb 7, 2013·Current Opinion in Hematology·Pierre Noel, Ruben A Mesa
Jul 5, 2005·Acta Haematologica·A Tefferi
Jan 1, 2015·Leukemia & Lymphoma·Delphine SauvageAlina Ferster
Jun 14, 2008·Expert Opinion on Investigational Drugs·Alfonso Quintás-Cardama, Jorge Cortes
Mar 28, 2012·Seminars in Hematology·Pierre Noel
Apr 14, 2006·Mayo Clinic Proceedings·Ayalew TefferiAnimesh Pardanani
Sep 25, 2007·Cancer Genetics and Cytogenetics·Yukitaka KatsuraToshiro Nagasawa
May 10, 2006·British Journal of Haematology·Ayalew TefferiAnimesh Pardanani
Jun 20, 2006·Best Practice & Research. Clinical Haematology·Jason GotlibD Gary Gilliland
Jan 24, 2017·British Journal of Haematology·Nauman M ButtUNKNOWN British Committee for Standards in Haematology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.